Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00577772 · ClinicalTrials.gov registry record · NA
Transit Time and Bacterial Overgrowth Using SmartPill Capsule
A NA study, sponsored by Mayo Clinic.
- Terminated
- Registry status
- NA
- Development phase
- 17
- Enrollment target
NCT00577772: Clinical Trial NA study, sponsored by Mayo Clinic.
NCT00577772 is a NA study that was terminated before completion, run by Mayo Clinic. The registered enrollment target is 17 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00577772, a NA study, was terminated before completion, sponsored by Mayo Clinic.
- TERMINATED
- Registry status
- NA
- Development phase
- 17 participants
- Enrollment target
Study Summary
The primary purpose of this exploratory study is to measure orocecal transit time using the SmartPill ambulant capsule technology and to compare this with the lactulose hydrogen breath test. Additionally, the ability of the SmartPill GI Monitoring System to discriminate between healthy human subjects and patients with small bowel bacterial overgrowth will be explored using analyses of both pH and pressure patterns within the stomach and small intestine. The study will be performed in both normal subjects and patients with and without small bowel bacterial overgrowth.
Interventions
- DRUG Xifaxan
- DEVICE SmartPill
- PROCEDURE Lactulose hydrogen breath test (H_2BT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2007-11 |
| Est. Completion | 2010-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00577772
The ClinicalTrials.gov registry entry for NCT00577772 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Xifaxan is the first listed.
NCT00577772 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00577772 about?
NCT00577772 is a clinical study titled "Transit Time and Bacterial Overgrowth Using SmartPill Capsule". The primary purpose of this exploratory study is to measure orocecal transit time using the SmartPill ambulant capsule technology and to compare this with the lactulose hydrogen breath test. Additionally, the ability of the SmartPill GI Monitoring System to discriminate between healthy human subject...
What is the current status of trial NCT00577772?
This trial is currently terminated. It is a NA study. The enrollment target is 17 participants. The study started on 2007-11. Estimated completion is 2010-07.
What interventions are being tested in trial NCT00577772?
The interventions under investigation include: Xifaxan (DRUG), SmartPill (DEVICE), Lactulose hydrogen breath test (H_2BT) (PROCEDURE).
Who is sponsoring clinical trial NCT00577772?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.